Calcium glubionate anhydrous API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Calcium glubionate anhydrous API 97635-31-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Calcium glubionate anhydrous. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Calcium glubionate anhydrous
- Synonyms:
- (D-gluconato)(lactobionato)calcium , Calcium D-gluconate lactobionate , Glubionate calcium
- Cas Number:
- 97635-31-9
- DrugBank number:
- DB13142
- Unique Ingredient Identifier:
- 93H20IU3DN
General Description:
Calcium glubionate anhydrous, identified by CAS number 97635-31-9, is a notable compound with significant therapeutic applications. Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets.
Indications:
This drug is primarily indicated for: Calcium glubionate is indicated to treat conditions caused by low calcium levels such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany). It may also be used in certain patients to make sure they are getting enough calcium (e.g, women who are pregnant, nursing, or postmenopausal, people taking certain medications such as phenytoin, phenobarbital, or prednisone). Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Absorption:
The absorption characteristics of Calcium glubionate anhydrous are crucial for its therapeutic efficacy: Minimal unless chronic, high doses; absorption predominantly in the duodenum and dependent on calcitriol and vitamin D; mean absorption of calcium intake varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, adults 25%); during pregnancy, calcium absorption doubles; calcium is absorbed in soluble, ionized form; solubility of calcium is increased in an acid environment (IOM 2011); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Protein Binding:
Calcium glubionate anhydrous exhibits a strong affinity for binding with plasma proteins: ~40%, primarily to albumin. This property plays a key role in the drug's pharmacokinetics and distribution within the body.
Route of Elimination:
The elimination of Calcium glubionate anhydrous from the body primarily occurs through: Primarily feces (75%; as unabsorbed calcium); urine (22%). Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Volume of Distribution:
Calcium glubionate anhydrous is distributed throughout the body with a volume of distribution of: Primarily in bones, teeth. This metric indicates how extensively the drug permeates into body tissues.
Mechanism of Action:
Calcium glubionate anhydrous functions by: Essential for nervous, muscular, and skeletal systems. Maintain cell membrane and capillary permeability. Act as an activator in the transmission of nerve impulses and contraction of cardiac, skeletal, and smooth muscle. Essential for bone formation and blood coagulation. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Categories:
Calcium glubionate anhydrous is categorized under the following therapeutic classes: Alimentary Tract and Metabolism, Calcium Salts, Carbohydrates, Mineral Supplements, Oligosaccharides, Polysaccharides. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Calcium glubionate anhydrous is a type of Electrolytes
Electrolytes are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) that play a vital role in maintaining the balance of essential ions in the body. These ions include sodium, potassium, calcium, magnesium, and chloride, among others. Electrolytes are responsible for maintaining proper hydration, regulating nerve and muscle function, and supporting various physiological processes.
In the pharmaceutical industry, electrolytes are widely utilized in the formulation of oral rehydration solutions, intravenous fluids, and dialysis solutions. These medications are employed to treat conditions such as dehydration, electrolyte imbalances, and renal dysfunction.
The availability of high-quality electrolyte APIs is of utmost importance to ensure the efficacy and safety of these pharmaceutical products. Pharmaceutical manufacturers rely on reputable suppliers who adhere to stringent quality control measures and comply with Good Manufacturing Practices (GMP) to produce electrolyte APIs of consistent quality.
To meet regulatory requirements, electrolyte APIs undergo rigorous testing to confirm their identity, purity, and potency. This includes analysis using advanced techniques such as high-performance liquid chromatography (HPLC), mass spectrometry (MS), and atomic absorption spectroscopy (AAS).
In conclusion, electrolytes are a vital category of pharmaceutical APIs used to maintain the balance of essential ions in the body. They are extensively employed in various medications aimed at treating dehydration, electrolyte imbalances, and renal dysfunction. Pharmaceutical manufacturers prioritize the use of high-quality electrolyte APIs to ensure the safety and efficacy of their products, and adherence to stringent regulatory standards is crucial in their production and testing processes.
